Profile
| Metric | Value |
|---|---|
| Full Name | PTC Therapeutics, Inc. |
| Ticker | NASDAQ: PTCT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | ptcbio.com |
| Employees | 939 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $75.40 | |
| Price, 1D Change | -2.82% | |
| Market Cap | $6B | |
| - | ||
| PE Ratio | 8.81 | |
| Beta | 0.93 | |
| Revenue | $807M | |
| Revenue, 1Y Change | -13.97% | |
| EPS | -$4.73 | |
| EPS, 1Y Change | +43.54% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.73 | |
| EPS Estimate | $8.82 | |
| EPS Est. Change | +286.46% | |
| Revenue | $806.78M | |
| Revenue Estimate | $1.82B | |
| Revenue Est. Change | +125.11% | |
| Current Price | $75.40 | |
| Price Target | - | $86.50 |
| Price Tgt. Change | - | +14.72% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.88 | -$8.37 | -42.39% | |
| -$3.91 | -$4.73 | -21.07% | |
| $8.82 | N/A | +286.46% | |
| -$0.80 | N/A | +83.11% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $945.21M | $937.82M | -0.78% | |
| $824.13M | $806.78M | -2.11% | |
| $1.82B | N/A | +125.11% | |
| $985.33M | N/A | +22.13% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +71.17% | |
| Price, 3Y | +57.81% | |
| Market Cap, 1Y | +76.86% | |
| Market Cap, 3Y | +73.31% | |
| Revenue, 1Y | -13.97% | |
| Revenue, 3Y | +49.79% | |
| EPS, 1Y | +43.54% | |
| EPS, 3Y | +36.41% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $75.40 | |
| SMA 200 | $58.24 | |
| SMA 200 vs Price | -22.76% | |
| SMA 50 | $76.23 | |
| SMA 50 vs Price | +1.10% | |
| Beta | 0.93 | |
| ATR | $2.98 | |
| 14-Day RSI | 45.06 | |
| 10-Day Volatility | 19.31% | |
| 1-Year Volatility | 50.30% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $806.78M | |
| EPS | -$4.73 | |
| Gross Profit | $688.64M | |
| Gross Margin | 85.36% | |
| Operating Profit | -$146.75M | |
| Operating Margin | -18.19% | |
| Net Income | -$363.30M | |
| Net Margin | -45.03% | |
| EBITDA | -$120.46M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -2.16 | |
| Current Ratio | 2.35 | |
| Quick Ratio | 2.31 | |
| - | ||
| F-Score | 6 | |
| Altman Z-Score | -1.04 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 8.81 | |
| PS Ratio | 3.40 | |
| PB Ratio | -38.87 | |
| EV/EBITDA | 5.00 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$1.10B | |
| Cash & Equivalents | $779.71M | |
| Total Assets | $1.72B | |
| Current Assets | $1.37B | |
| Total Liabilities | $2.81B | |
| Current Liabilities | $580.98M | |
| Total Debt | $389.30M | |
| Short Term Debt | $13.36M | |
| Accounts Payable | $17.27M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $953.53M | |
| Operating Expenses | $896.13M | |
| Cost Of Goods Sold | $118.14M | |
| SG&A | $300.91M | |
| D&A | $75.66M | |
| Interest Expense | $0.00 | |
| Income Tax | $176.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$107.69M | |
| CFI | $44.18M | |
| CFF | $255.87M | |
| Capex | $74.25M | |
| Free Cash Flow | -$181.94M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| RBC Capital | → | |
| Barclays | → | |
| Wells Fargo | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Goldman Sachs | → | |
| Citigroup | → | |
| Jefferies | → | |
| Cantor Fitzgerald | → | |
| Wells Fargo | → |
Analyst sentiment
Institutional ownership
Screeners with PTCT
Data Sources & References
- PTCT Official Website www.ptcbio.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1070081/000107008125000028/0001070081-25-000028-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1070081/000107008125000012/0001070081-25-000012-index.htm
- PTCT Profile on Yahoo Finance finance.yahoo.com/quote/PTCT
- PTCT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ptct
FAQ
What is the ticker symbol for PTC Therapeutics, Inc.?
The ticker symbol for PTC Therapeutics, Inc. is NASDAQ:PTCT
Does PTC Therapeutics, Inc. pay dividends?
No, PTC Therapeutics, Inc. does not pay dividends
What sector is PTC Therapeutics, Inc. in?
PTC Therapeutics, Inc. is in the Healthcare sector
What industry is PTC Therapeutics, Inc. in?
PTC Therapeutics, Inc. is in the Biotechnology industry
What country is PTC Therapeutics, Inc. based in?
PTC Therapeutics, Inc. is headquartered in United States
When did PTC Therapeutics, Inc. go public?
PTC Therapeutics, Inc. initial public offering (IPO) was on June 20, 2013
Is PTC Therapeutics, Inc. in the S&P 500?
No, PTC Therapeutics, Inc. is not included in the S&P 500 index
Is PTC Therapeutics, Inc. in the NASDAQ 100?
No, PTC Therapeutics, Inc. is not included in the NASDAQ 100 index
Is PTC Therapeutics, Inc. in the Dow Jones?
No, PTC Therapeutics, Inc. is not included in the Dow Jones index
When was PTC Therapeutics, Inc. last earnings report?
PTC Therapeutics, Inc.'s most recent earnings report was on November 4, 2025
When does PTC Therapeutics, Inc. report earnings?
The next expected earnings date for PTC Therapeutics, Inc. is February 26, 2026